Table 2 Details of the antiplatelet and anticoagulant therapies
n = 149 | (%) | ||
|---|---|---|---|
Single | Antiplatelet | ||
Aspirin | 65 | (43.6) | |
Cilostazol | 7 | (4.7) | |
Clopidogrel | 5 | (3.4) | |
Ticlopidine | 3 | (2.0) | |
Total | 80 | (53.7) | |
Anticoagulant | |||
Warfarin | 25 | (16.8) | |
Rivaroxaban | 4 | (2.7) | |
Dabigatran | 4 | (2.7) | |
Apixaban | 1 | (0.7) | |
Total | 34 | (22.8) | |
Dual | Dual antiplatelet therapy | ||
Aspirin + Clopidogrel | 14 | (9.4) | |
Aspirin + Ticlopidine | 3 | (2.0) | |
Aspirin + Cilostazol | 2 | (1.3) | |
Total | 19 | (12.8) | |
Antiplatelet + Anticoagulant | |||
Aspirin + Warfarin | 10 | (6.7) | |
Other combinations | 6 | (4.0) | |
Total | 16 | (10.7) | |